BlueCrest Capital Management Ltd Buys Shares of 6,453 PerkinElmer, Inc. (PKI)
BlueCrest Capital Management Ltd bought a new position in PerkinElmer, Inc. (NYSE:PKI) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 6,453 shares of the medical research company’s stock, valued at approximately $440,000.
Other hedge funds also recently modified their holdings of the company. Envestnet Asset Management Inc. grew its stake in PerkinElmer by 28.1% in the 1st quarter. Envestnet Asset Management Inc. now owns 1,979 shares of the medical research company’s stock worth $115,000 after acquiring an additional 434 shares in the last quarter. Acrospire Investment Management LLC grew its stake in PerkinElmer by 185.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 2,000 shares of the medical research company’s stock worth $136,000 after acquiring an additional 1,300 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in PerkinElmer in the 1st quarter worth about $152,000. LS Investment Advisors LLC grew its stake in PerkinElmer by 2.1% in the 2nd quarter. LS Investment Advisors LLC now owns 2,877 shares of the medical research company’s stock worth $196,000 after acquiring an additional 60 shares in the last quarter. Finally, Capital Asset Advisory Services LLC bought a new position in PerkinElmer in the 2nd quarter worth about $222,000. Institutional investors and hedge funds own 91.47% of the company’s stock.
Several brokerages have recently weighed in on PKI. Cowen and Company reaffirmed a “market perform” rating and issued a $70.00 price target (up previously from $61.00) on shares of PerkinElmer in a research report on Tuesday, June 20th. Wells Fargo & Company began coverage on shares of PerkinElmer in a research report on Thursday, July 13th. They issued a “market perform” rating and a $72.00 price target for the company. Zacks Investment Research cut shares of PerkinElmer from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $67.00 price target on shares of PerkinElmer in a research report on Tuesday, September 26th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating on shares of PerkinElmer in a research report on Sunday, July 16th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $67.77.
PerkinElmer, Inc. (NYSE:PKI) opened at 71.25 on Tuesday. PerkinElmer, Inc. has a 12-month low of $45.35 and a 12-month high of $72.11. The firm has a 50 day moving average of $68.78 and a 200-day moving average of $64.95. The stock has a market cap of $7.85 billion, a PE ratio of 21.49 and a beta of 0.72.
PerkinElmer (NYSE:PKI) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The business had revenue of $547.00 million during the quarter, compared to the consensus estimate of $554.14 million. PerkinElmer had a net margin of 16.80% and a return on equity of 13.44%. The company’s revenue was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 EPS. On average, analysts expect that PerkinElmer, Inc. will post $2.89 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 10th. Stockholders of record on Friday, October 20th will be given a dividend of $0.07 per share. The ex-dividend date is Thursday, October 19th. This represents a $0.28 annualized dividend and a dividend yield of 0.39%. PerkinElmer’s dividend payout ratio is presently 8.46%.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.